Extended Data Fig. 8: Capacity of baseline variables in discriminating participant’s responsiveness to imatinib therapy.

(a-h) Comparison of available baseline clinical/biochemical features to assess their potential in stratifying clinical trial participants to two treatment response groups – those that were in the Lower Quartile (LQ) of drug response (blue, n = 11/group, panel d with n = 10) vs those in the Upper Quartile (UQ) of the drug response (orange, n = 11). Statistical significance is presented based on two-sided Welch’s t-test between the two groups. Data presents the minimum, 25^th percentile, median, 75^th percentile and maximum values in the box and whiskers graphs. (i) A dimensionality reduction algorithm was used to see if all available baseline clinical variables together could stratify the LQ (n = 11) and UQ (n = 11) participants. DV=dependant variables. (j) The expression of 17 of the PREDICT T1D microRNAs (indicated on the Y-axis) was significantly different across the UQ (n = 11) and LQ (n = 11) of imatinib clinical trial participants. All microRNAs (most targeting tyrosine kinase) were significantly higher in participants who best responded to imatinib therapy. Statistical significance across the two groups is presented for each microRNA comparison based on a one-sided Welch’s t-test. Data presents the median (red solid line), quartiles (blue dotted line) and distribution in the violin plots.